EVGN Stock Forecast: Evogene Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.32
+2.00% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$5.8M
Ticker Nerd rank
38/ 100
Median analyst target
$2.15
Analysts covering
—
Revenue$347K−60.7% y/y
Operating income−$2.6M
Net income−$1.8M
Free cash flow−$2.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.5%
1M
−14.5%
YTD
−71.3%
1Y
−70.7%
From 52W high
−72.5%
From 52W low
+17.1%
$0.27
$1.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Evogene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
92
Revisions
84
Issuance
48
Momentum
25
Volatility
23
Growth
16
Quality
8
Value
2

Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EVGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00Jan 26Apr 26Jul 26Oct 26EVGNHigh $2.15Median $2.15Low $2.15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 May 2025Lake StreetMaintainsBuy$5.00 → $3.50
23 Aug 2024Lake StreetMaintainsBuy—
2 Oct 2023Alliance Global PartnersInitiatesBuy—
18 Aug 2023Lake StreetMaintainsBuy—
21 July 2023Roth MKMMaintainsBuy—
2 May 2023Lake StreetInitiatesBuy—
12 Sept 2022Aegis CapitalMaintainsBuy—
2 Sept 2022Roth MKMMaintainsBuy—
8 Oct 2021Roth CapitalInitiatesBuy—
29 July 2021Aegis CapitalInitiatesBuy—
1 Dec 2020Cantor FitzgeraldInitiatesOverweight—
12 Nov 2014Credit SuisseMaintainsOutperform$24 → $22
17 Dec 2013Deutsche BankInitiatesBuy—
16 Dec 2013Credit SuisseInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

EVGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EVGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Evogene Ltd. returned −70.7% against +6.9% for the S&P 500, dividends included.

EVGN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26EVGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EVGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.8×

Cheaper than 28% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
40.6%

Higher than 50% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−151.3%

Higher than 9% of US stocks

Return on assets
−48.0%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evogene Ltd. has a market value of $5.8M and an enterprise value of $7.4M.

  • Revenue in the twelve months to 30 June 2026: $1.3M. The latest quarter shrank 60.7% year on year.

  • Net income over the same four quarters: −$7.8M, a −598.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.91.

  • Free cash flow in the twelve months to 30 June 2026: −$11.0M.

  • Shares outstanding: 13.5M.

  • Evogene Ltd. employs 52 people — $25K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

EVGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EVGNEvogene Ltd.$5.8M38
XCURExicure, Inc.$5.7M61
TPSTTempest Therapeutics, Inc.$5.7M53
LGVNLongeveron, Inc.$5.6M44
TOVXTheriva Biologics, Inc.$5.5M30
OPHICollPlant Biotechnologies Ltd.$5.9M28
ENVBEnveric Biosciences, Inc.$6.0M16

Take a look at EVGN’s peer groups, ranked by the model: materials stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Evogene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about EVGN

How does Ticker Nerd's model rank EVGN?

As at 21 Nov 2026, Evogene Ltd. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).

What is the EVGN stock forecast for 2030?

No analyst covering Evogene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.15 to $2.15 over the next 12 months.

How has EVGN stock performed over the past year?

Evogene Ltd. returned -70.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evogene Ltd. do?

Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications.

Company

About Evogene Ltd.

Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications. Its current business is organized around three segments: Agriculture, Human Health, and Industrial Applications. In agriculture, the company works on crop-improvement solutions such as seed traits and biological or chemical inputs that support plant performance. In human health, it develops microbiome-based therapeutics and related discovery programs. In industrial applications, it pursues specialized biological and seed-based solutions for non-food uses. Headquartered in Rehovot, Israel, Evogene serves as a technology platform company that applies computational methods to accelerate product discovery across multiple sectors.

CEO Mr. Ofer Haviv CPA · 52 employees · Israel · https://www.evogene.com